146 related articles for article (PubMed ID: 38108390)
1. Immunohistochemical Expression of Immune Checkpoints; CTLA-4, LAG3, and TIM-3 in Cancer Cells and Tumor-infiltrating Lymphocytes (TILs) in Colorectal Carcinoma.
Abdelrahman DI; Elhasadi I; Anbaig A; Bakry A; Mandour D; Wasefy T; Yehia AM; Alorini M; Shalaby AM; Yahia AIO; Alabiad MA
Appl Immunohistochem Mol Morphol; 2024 Feb; 32(2):71-83. PubMed ID: 38108390
[TBL] [Abstract][Full Text] [Related]
2. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer.
Mollavelioglu B; Cetin Aktas E; Cabioglu N; Abbasov A; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen V
World J Surg Oncol; 2022 Oct; 20(1):349. PubMed ID: 36271406
[TBL] [Abstract][Full Text] [Related]
3. The role and relationship between programmed death ligand 1 and cytotoxic T lymphocyte-associated antigen-4 immunohistochemical expression in colorectal carcinoma patients: an impact on outcome.
El Dein Mohameda AS; El-Rebey HS; AboElnasr LSA; Abdou AG
Ecancermedicalscience; 2021; 15():1323. PubMed ID: 35047074
[TBL] [Abstract][Full Text] [Related]
4. Genetic signature of CTLA-4, BTLA, TIM-3 and LAG-3 molecular expression in colorectal cancer patients: Implications in diagnosis and survival outcomes.
Kamal AM; Wasfey EF; Elghamry WR; Sabry OM; Elghobary HA; Radwan SM
Clin Biochem; 2021 Oct; 96():13-18. PubMed ID: 34217699
[TBL] [Abstract][Full Text] [Related]
5. TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer.
Cabioglu N; Onder S; Oner G; Karatay H; Tukenmez M; Muslumanoglu M; İgci A; Eralp Y; Aydiner A; Saip P; Yavuz E; Ozmen V
BMC Cancer; 2021 Apr; 21(1):357. PubMed ID: 33823818
[TBL] [Abstract][Full Text] [Related]
6. Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.
Shi X; Li CW; Tan LC; Wen SS; Liao T; Zhang Y; Chen TZ; Ma B; Yu PC; Lu ZW; Qu N; Wang Y; Shi RL; Wang YL; Ji QH; Wei WJ
J Clin Endocrinol Metab; 2021 Jan; 106(1):120-132. PubMed ID: 33000173
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoints in Circulating and Tumor-Infiltrating CD4
Toor SM; Murshed K; Al-Dhaheri M; Khawar M; Abu Nada M; Elkord E
Front Immunol; 2019; 10():2936. PubMed ID: 31921188
[TBL] [Abstract][Full Text] [Related]
8. Presence of Tim3
Klapholz M; Drage MG; Srivastava A; Anderson AC
J Pathol; 2022 Jun; 257(2):186-197. PubMed ID: 35119692
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint proteins (PD-L1 and CTLA-4) in endometrial carcinoma: prognostic role and correlation with CD4
Khalifa R; Elsese N; El-Desouky K; Shaair H; Helal D
J Immunoassay Immunochem; 2022 Mar; 43(2):192-212. PubMed ID: 34697997
[TBL] [Abstract][Full Text] [Related]
10. Lymphocyte-activated gene-3 (LAG3) protein expressed in tumor-infiltrating lymphocytes of colorectal cancer.
Xu J; Shen D; Zhang T; Wang J; De W; Zhang J
Pol J Pathol; 2021; 72(4):324-330. PubMed ID: 35308003
[TBL] [Abstract][Full Text] [Related]
11. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.
Guo XJ; Lu JC; Zeng HY; Zhou R; Sun QM; Yang GH; Pei YZ; Meng XL; Shen YH; Zhang PF; Cai JB; Huang PX; Ke AW; Shi YH; Zhou J; Fan J; Chen Y; Yang LX; Shi GM; Huang XY
Front Immunol; 2021; 12():705378. PubMed ID: 34526987
[TBL] [Abstract][Full Text] [Related]
12. [Relationship Between Tim-3 and Galectin-9 Expression Levels, Clinical Pathological Characteristics, and Prognosis in Patients After Radical Resection of Colorectal Cancer].
Zhang Y; Deng D; Yin W; Luo J; Liu J; Xie C; Ji X; Ma L; Zhang L; Xia X; Cheng S; Huang A; Yang F
Sichuan Da Xue Xue Bao Yi Xue Ban; 2024 Mar; 55(2):375-382. PubMed ID: 38645842
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Implications of Immune Infiltrates in the Breast Cancer Microenvironment: The Role of Expressions of CTLA-4, PD-1, and LAG-3.
Bagbudar S; Karanlik H; Cabioglu N; Bayram A; Ibis K; Aydin E; Yavuz E; Onder S
Appl Immunohistochem Mol Morphol; 2022 Feb; 30(2):99-107. PubMed ID: 34608875
[TBL] [Abstract][Full Text] [Related]
14. LAG-3, TIM-3 and VISTA Expression on Tumor-Infiltrating Lymphocytes in Oropharyngeal Squamous Cell Carcinoma-Potential Biomarkers for Targeted Therapy Concepts.
Wuerdemann N; Pütz K; Eckel H; Jain R; Wittekindt C; Huebbers CU; Sharma SJ; Langer C; Gattenlöhner S; Büttner R; Speel EJ; Suchan M; Wagner S; Quaas A; Klussmann JP
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396515
[TBL] [Abstract][Full Text] [Related]
15. T-Cell Immunoglobulin Mucin 3 Expression on Tumor Infiltrating Lymphocytes as a Positive Prognosticator in Triple-Negative Breast Cancer.
Byun KD; Hwang HJ; Park KJ; Kim MC; Cho SH; Ju MH; Lee JH; Jeong JS
J Breast Cancer; 2018 Dec; 21(4):406-414. PubMed ID: 30607162
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological features and prognostic analysis of 247 small cell lung cancer with limited-stage after surgery.
Liu L; Wei J; Teng F; Zhu Y; Xing P; Zhang J; Guo Y; Dong J; Ying J; Li J; Yang L
Hum Pathol; 2021 Feb; 108():84-92. PubMed ID: 33245986
[TBL] [Abstract][Full Text] [Related]
17. Low Distribution of TIM-3
Zhuang C; Ni B; Zhang ZZ; Zhao WY; Tu L; Ma XL; Yang LX; Cao H; Wang M
J Immunol Res; 2021; 2021():6647292. PubMed ID: 33681387
[TBL] [Abstract][Full Text] [Related]
18. Circulating and Tumor-Infiltrating Immune Checkpoint-Expressing CD8
Alsalman A; Al-Mterin MA; Murshed K; Alloush F; Al-Shouli ST; Toor SM; Elkord E
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804964
[TBL] [Abstract][Full Text] [Related]
19. Co-expression of PD-1 with TIGIT or PD-1 with TIM-3 on tumor-infiltrating CD8
Meyiah A; Mahmoodi Chalbatani G; Al-Mterin MA; Malekraeisi MA; Murshed K; Elkord E
Int Immunopharmacol; 2023 Jun; 119():110207. PubMed ID: 37099940
[TBL] [Abstract][Full Text] [Related]
20. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma.
Liu F; Zeng G; Zhou S; He X; Sun N; Zhu X; Hu A
Bull Cancer; 2018 May; 105(5):493-501. PubMed ID: 29576222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
